Mary M. Rozenman, See Remarks at Aimmune Therapeutics, Inc. (AIMT), sold 14,940 shares at $21.38 ($320K) on 2017-07-17, disclosed to the SEC on 2017-07-17.
Scheduled sale ($320k) by See Remarks under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $21.47 | 8,974 | $193K | 60.2% |
| 2 | $21.39 | 5,666 | $121K | 37.8% |
| 3 | $21.38 | 300 | $6K | 2.0% |
| Total | $21.44 avg | 14,940 | $320K | 100% |
| Filing → |
| AIMT | SELL | 2018-01-04 | $489K | — | Filing → |
| AIMT | SELL | 2017-12-28 | $381K | — | Filing → |
| AIMT | SELL | 2017-09-11 | $675K | — | Filing → |